Insider Trading February 5, 2026

Graco Executive Disposes $195,759 in Stock; Also Exercises Options

CIO Kathryn Schoenrock sells shares and exercises options as company posts Q4 2025 in line with estimates

By Jordan Park GGG
Graco Executive Disposes $195,759 in Stock; Also Exercises Options
GGG

Kathryn L. Schoenrock, Executive Vice President and Chief Information Officer of Graco Inc (NYSE: GGG), sold 2,223 shares on February 2, 2026, for $195,759 and exercised options for 3,336 shares the same day. Graco reported fourth-quarter 2025 EPS of $0.77 and revenue of $593.2 million, slightly above expectations, with management citing acquisitions and operational efficiencies for the performance.

Key Points

  • Kathryn L. Schoenrock sold 2,223 shares of Graco common stock on February 2, 2026, at prices between $88.00 and $88.124, totaling $195,759.
  • On the same day she exercised options to acquire 3,336 shares at an exercise price of $23.8467, totaling $79,552.
  • Graco reported Q4 2025 EPS of $0.77, meeting analysts' expectations, and revenue of $593.2 million, slightly above forecasts, with the company citing acquisitions and operational efficiencies as drivers of performance.

Kathryn L. Schoenrock, who serves as Executive Vice President and Chief Information Officer at Graco Inc (NYSE: GGG), completed a stock sale on February 2, 2026, disposing of 2,223 shares of common stock, according to a recent SEC filing. The sold shares fetched prices between $88.00 and $88.124 per share, producing gross proceeds of $195,759.

That same day Schoenrock exercised outstanding options to acquire 3,336 shares of Graco common stock at an exercise price of $23.8467 per share. The exercise carried a total notional value of $79,552.

Separately, Graco released its fourth-quarter 2025 financial results, reporting earnings per share of $0.77, a figure that met analysts' consensus. The company reported revenue of $593.2 million, which modestly exceeded revenue forecasts. The earnings release attributed the outperformance to recent acquisitions and improved operational efficiencies, noting these factors helped offset headwinds in a challenging market environment.

Market response to the results was positive for the stock, though commentary around the quarter emphasized continued attention on Graco's longer-term strategic execution. Analysts cited the quarter as evidence that the company is maintaining a steady growth trajectory. The earnings report was described as showing resilience and adaptability in a fluctuating market, and investors remain focused on how Graco will build on these operational and acquisition-related gains in upcoming quarters.


Context and implications

The filing documenting Schoenrock's sale and option exercise provides a contemporaneous view of an insider transaction tied to the same period as the company's quarterly disclosure. The transactions and the earnings announcement appear together in public records, with the financial report offering the backdrop against which investors and analysts are assessing company momentum.

While the insider activity documents specific share counts, exercise prices, and proceeds, the company's quarterly metrics quantify near-term financial performance. Observers tracking insider moves and earnings trends will likely consider both sets of information as they evaluate Graco's outlook.

Risks

  • Market conditions remain challenging, which could affect future quarters if acquisitions and operational efficiencies do not continue to mitigate headwinds - this impacts industrial and manufacturing sectors tied to Graco's business.
  • Insider transactions may draw scrutiny from investors assessing management incentive alignment, which could influence investor sentiment toward the stock - this affects equity market perception of Graco (GGG).

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026